EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond

Anders Edsjö, Hege G Russnes, Janne Lehtiö, David Tamborero, Eivind Hovig, Albrecht Stenzinger iD, Richard Rosenquist iD, PCM4EU consortium

Journal of Internal Medicine · 2024-06 · 295 (6) · 785-803

DOI: 10.1111/joim.13785 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 02.05.2024. Verfasst von Anders Edsjö und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU4Health programme as part of Europe's Beating Cancer Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decades, the development of high‐throughput molecular assays has revolutionised cancer diagnostics, paving the way for the concept of personalised cancer medicine. This progress has been driven by the introduction of such technologies through biomarker‐driven oncology trials. In this review, strengths and limitations of various state‐of‐the‐art sequencing technologies, including gene panel sequencing (DNA and RNA), whole‐exome/whole‐genome sequencing and whole‐transcriptome sequencing, are explored, focusing on their ability to identify clinically relevant biomarkers with diagnostic, prognostic and/or predictive impact. This includes the need to assess complex biomarkers, for example microsatellite instability, tumour mutation burden and homologous recombination deficiency, to identify patients suitable for specific therapies, including immunotherapy. Furthermore, the crucial role of biomarker analysis and multidisciplinary molecular tumour boards in selecting patients for trial inclusion is discussed in relation to various trial concepts, including drug repurposing. Recognising that today's exploratory techniques will evolve into tomorrow's routine diagnostics and clinical study inclusion assays, the importance of emerging technologies for multimodal diagnostics, such as proteomics and in vivo drug sensitivity testing, is also discussed. In addition, key regulatory aspects and the importance of patient engagement in all phases of a clinical trial are described. Finally, we propose a set of recommendations for consideration when planning a new precision cancer medicine trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineNeoplasmsBiomarkers, TumorHumansHigh-Throughput Nucleotide SequencingClinical Trials as TopicMedical Oncology

Stichwörter der Autor:innen

biomarkersclinical trialsomics technologiespersonalised oncologyprecision cancer medicineprecision diagnostics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.
  • Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Department of Pathology, Oslo University Hospital, Oslo, Norway.
  • Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden.

ORCID-Profile: Albrecht Stenzinger, Richard Rosenquist

Förderung

  • EU4Health programme as part of Europe's Beating Cancer Plan

Zitieren

APA

Edsjö, A., Russnes, H. G., Lehtiö, J., Tamborero, D., Hovig, E., Stenzinger, A., Rosenquist, R., & PCM4EU consortium (2024). High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond. Journal of Internal Medicine, 295(6), 785-803. https://doi.org/10.1111/joim.13785

Vancouver

Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, Stenzinger A, et al. High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond. Journal of Internal Medicine. 2024;295(6):785-803. doi:10.1111/joim.13785

BibTeX
@article{Edsj2024,
  author = {Edsjö, Anders and Russnes, Hege G and Lehtiö, Janne and Tamborero, David and Hovig, Eivind and Stenzinger, Albrecht and Rosenquist, Richard and PCM4EU consortium, PCM4EU consortium},
  title = {High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond},
  journal = {Journal of Internal Medicine},
  year = {2024},
  volume = {295},
  number = {6},
  pages = {785--803},
  doi = {10.1111/joim.13785}
}
Kostenlos starten →